483
Janssen Biotech, Inc.FDA 483 - Janssen Biotech, Inc. - May 18, 2017
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
During an inspection, Janssen Biotech, Inc. in Malvern, PA was cited for incomplete written records of investigations. Specifically, the firm failed to adequately investigate out-of-specification batches of Bovine APO Transferrin and a decrease in process capability for API Pre-formulated Bulk Bioactivity Assay. These issues indicate deficiencies in the firm's quality control unit and investigation procedures.
Open in Dashboard
ID · 49d46fef-c43c-4edf-92a6-85e4dd41c6cb